Company intelligence / Profile preview

Matterhorn Biosciences

Allschwil, Basel-Landschaft, Switzerland

Ownership: Private
Employees: ~30
Development stage: Other

Overview

The company has not yet reported clinical trial results; its lead MR1-restricted T cell receptor programs are in preclinical and IND-enabling stages with no completed human trials as of the latest public data[2][3][4].

Therapeutic areas: Oncology
Modalities: Cell therapyT cell receptor engineered T cell therapy
Industry: Biotech

Beyond the preview

Go deeper on Matterhorn Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Matterhorn Biosciences.

Explore the full profile